专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080187578A1 Platinum Aggregates and Process for Producing the Same 有权
标题翻译：白金聚集体及其生产方法
公开(公告)号：US20080187578A1
公开(公告)日：2008-08-07
申请号：US12027752
申请日：2008-02-07
申请人： Jin K. Lee , Brian S. Miller , Fangjun Wu , Lawrence T. Boni , Vladimir Malinin
发明人： Jin K. Lee , Brian S. Miller , Fangjun Wu , Lawrence T. Boni , Vladimir Malinin
IPC分类号： A61K9/127 , A61K33/24 , A61K31/28
CPC分类号： A61K9/127 , A61K9/0078 , A61K9/1277 , A61K31/28 , A61K33/24 , A61K47/544 , A61K47/554
摘要： One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome. The liposome may comprise at least one lipid, and may further comprise at least one active platinum compound. The disclosure also relates to a pharmaceutical formulation comprising a lipid complexed active platinum compound and a pharmaceutically acceptable carrier or diluent. The pharmaceutical formulation may be formulated for inhalation or injection.
摘要翻译：本公开的一个方面涉及脂质复合的活性铂化合物的新形式，其允许组合物中高浓度的铂化合物。例如，与1mg / mL的水溶液相比，组合物中顺铂的浓度在室温较高，例如大于1.2mg / mL。在一个实施方案中，本发明涉及包含脂质复合的活性铂化合物的组合物，其中所述复合物具有小于约1重量比的脂质与药物（L / D）比例，例如。约0.10至1，其中所述脂质复合的活性铂化合物包含至少一种脂质和至少一种活性铂化合物。在其它实施方案中，其中脂质配合的活性铂化合物的平均体积加权直径为约0.5至约20微米。在其它实施方案中，组合物还包含脂质体。脂质体可以包含至少一种脂质，并且还可以包含至少一种活性铂化合物。本公开还涉及包含脂质复合的活性铂化合物和药学上可接受的载体或稀释剂的药物制剂。药物制剂可以配制用于吸入或注射。

2. 发明授权

US09186322B2 Platinum aggregates and process for producing the same 有权
标题翻译：铂集合体及其生产方法
公开(公告)号：US09186322B2
公开(公告)日：2015-11-17
申请号：US12027752
申请日：2008-02-07
申请人： Jin K. Lee , Brian S. Miller , Fangjun Wu , Lawrence T. Boni , Vladimir Malinin
发明人： Jin K. Lee , Brian S. Miller , Fangjun Wu , Lawrence T. Boni , Vladimir Malinin
IPC分类号： A61K9/127 , A61K9/00 , A61K31/28 , A61K33/24 , A61K47/48
CPC分类号： A61K9/127 , A61K9/0078 , A61K9/1277 , A61K31/28 , A61K33/24 , A61K47/544 , A61K47/554
摘要： One aspect of the disclosure relates to a new form of lipid-complexed active platinum compound, which allows for high concentrations of platinum compound in the composition. For example, the concentration of cisplatin in the composition is higher at room temperature, e.g., about greater than 1.2 mg/mL, compared to 1 mg/mL in aqueous solution. In one embodiment, the present invention is directed to a composition comprising a lipid-complexed active platinum compound, wherein the complex has a lipid to drug (L/D) ratio of less than about 1 by weight, e.g. about 0.10 to 1, wherein the lipid-complexed active platinum compound comprises at least one lipid and at least one active platinum compound. In other embodiments, wherein lipid-complexed active platinum compound has an average volume-weighted diameter of about 0.5 to about 20 microns. In still other embodiments, the composition further comprises a liposome. The liposome may comprise at least one lipid, and may further comprise at least one active platinum compound. The disclosure also relates to a pharmaceutical formulation comprising a lipid complexed active platinum compound and a pharmaceutically acceptable carrier or diluent. The pharmaceutical formulation may be formulated for inhalation or injection.
摘要翻译：本公开的一个方面涉及脂质复合的活性铂化合物的新形式，其允许组合物中高浓度的铂化合物。例如，与1mg / mL的水溶液相比，组合物中顺铂的浓度在室温较高，例如大于1.2mg / mL。在一个实施方案中，本发明涉及包含脂质复合的活性铂化合物的组合物，其中所述复合物具有小于约1重量比的脂质与药物（L / D）比例，例如。约0.10至1，其中所述脂质复合的活性铂化合物包含至少一种脂质和至少一种活性铂化合物。在其它实施方案中，其中脂质配合的活性铂化合物的平均体积加权直径为约0.5至约20微米。在其它实施方案中，组合物还包含脂质体。脂质体可以包含至少一种脂质，并且还可以包含至少一种活性铂化合物。本公开还涉及包含脂质复合的活性铂化合物和药学上可接受的载体或稀释剂的药物制剂。药物制剂可以配制用于吸入或注射。

3. 发明授权

US07879351B2 High delivery rates for lipid based drug formulations, and methods of treatment thereof 有权
标题翻译：基于脂质的药物制剂的高递送率及其治疗方法
公开(公告)号：US07879351B2
公开(公告)日：2011-02-01
申请号：US11398859
申请日：2006-04-06
申请人： Zhili Li , Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
发明人： Zhili Li , Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
IPC分类号： A61K9/127
CPC分类号： A61K9/0078 , A61K9/127 , A61K9/1617 , A61K9/5015 , A61K9/5123 , A61K31/7034 , A61K31/7036 , Y02A50/406 , Y02A50/473
摘要： Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.
摘要翻译：提供了使用凝聚技术制备具有低脂/药物比例的基于脂质的药物制剂的方法。还提供了以高递送速率递送这种基于脂质的药物制剂的方法，以及治疗患有肺部疾病的患者的方法，包括施用这种基于脂质的药物制剂。

4. 发明授权

US08802137B2 Sustained release of antiinfectives 有权
标题翻译：持续释放抗感染药
公开(公告)号：US08802137B2
公开(公告)日：2014-08-12
申请号：US12748756
申请日：2010-03-29
申请人： Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
发明人： Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
IPC分类号： A61K9/127 , A61K31/407 , A61K9/00 , A61K31/496 , A61K31/704 , A61K31/545 , A61K31/4709
CPC分类号： A61K47/28 , A61K9/0078 , A61K9/127 , A61K9/1277 , A61K31/407 , A61K31/4709 , A61K31/496 , A61K31/545 , A61K31/7036 , A61K31/704 , A61K45/06 , Y02A50/473
摘要： Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.
摘要翻译：提供基本上不含阴离子脂质的脂质抗感染制剂，其脂质与抗感染比为约1:1至约4:1，平均平均直径小于约1μm。还提供了制备包含输注方法的脂质抗感染制剂的方法。还提供了脂质抗感染制剂，其中通过在线融合方法制备的脂质与药物的比例为约1:1或更低，约0.75:1或更低，或约0.50:1或更低。本发明还涉及治疗患有肺部感染的患者的方法，其包括向患者施用治疗有效量的本发明的抗脂质抗感染药物。本发明还涉及一种治疗患者囊性纤维化的方法，其包括向患者施用治疗有效量的本发明的抗脂质抗感染制剂。

5. 发明申请

US20110159079A1 High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof 审中-公开
标题翻译：基于脂质药物制剂的高递送率及其治疗方法
公开(公告)号：US20110159079A1
公开(公告)日：2011-06-30
申请号：US12983659
申请日：2011-01-03
申请人： Zhili Li , Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
发明人： Zhili Li , Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
IPC分类号： A61K9/127 , A61K47/44 , A61P31/00 , A61P11/00
CPC分类号： A61K9/0078 , A61K9/127 , A61K9/1617 , A61K9/5015 , A61K9/5123 , A61K31/7034 , A61K31/7036 , Y02A50/406 , Y02A50/473
摘要： Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.
摘要翻译：提供了使用凝聚技术制备具有低脂/药物比例的基于脂质的药物制剂的方法。还提供了以高递送速率递送这种基于脂质的药物制剂的方法，以及治疗患有肺部疾病的患者的方法，包括施用这种基于脂质的药物制剂。

6. 发明授权

US07718189B2 Sustained release of antiinfectives 有权
标题翻译：持续释放抗感染药
公开(公告)号：US07718189B2
公开(公告)日：2010-05-18
申请号：US11185448
申请日：2005-07-19
申请人： Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
发明人： Lawrence T. Boni , Brian S. Miller , Vladimir Malinin , Xingong Li
IPC分类号： A61K9/127
CPC分类号： A61K47/28 , A61K9/0078 , A61K9/127 , A61K9/1277 , A61K31/407 , A61K31/4709 , A61K31/496 , A61K31/545 , A61K31/7036 , A61K31/704 , A61K45/06 , Y02A50/473
摘要： Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.
摘要翻译：提供基本上不含阴离子脂质的脂质抗感染制剂，其脂质与抗感染比为约1:1至约4:1，平均平均直径小于约1μm。还提供了制备包含输注方法的脂质抗感染制剂的方法。还提供了脂质抗感染制剂，其中通过在线融合方法制备的脂质与药物的比例为约1:1或更低，约0.75:1或更低，或约0.50:1或更低。本发明还涉及治疗患有肺部感染的患者的方法，其包括向患者施用治疗有效量的本发明的抗脂质抗感染药物。本发明还涉及一种治疗患者囊性纤维化的方法，其包括向患者施用治疗有效量的本发明的抗脂质抗感染制剂。

7. 发明授权

US07544369B2 Sustained release of antiinfectives 有权
标题翻译：持续释放抗感染药
公开(公告)号：US07544369B2
公开(公告)日：2009-06-09
申请号：US10696389
申请日：2003-10-29
申请人： Lawrence T. Boni , Brian S. Miller
发明人： Lawrence T. Boni , Brian S. Miller
IPC分类号： A61K9/127
CPC分类号： A61K31/7036 , A61K9/0073 , A61K9/0078 , A61K9/127 , A61K31/407 , A61K31/496 , A61K31/545 , Y02A50/406 , Y02A50/473 , Y10S977/773 , Y10S977/906 , Y10S977/907
摘要： Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
摘要翻译：提供了一种治疗或改善囊性纤维化患者肺部感染的方法，包括向患者肺部施用有效量的脂质体/复合抗感染药，其中（i）给药量为50％或更少比较游离药物量，或（ii）给药是每天一次或更少，或（iii）两者。

8. 发明申请

US20100068257A1 Sustained Release of Antiinfectives 审中-公开
标题翻译：持续释放抗感染药
公开(公告)号：US20100068257A1
公开(公告)日：2010-03-18
申请号：US12424177
申请日：2009-04-15
申请人： Lawrence T. Boni , Brian S. Miller
发明人： Lawrence T. Boni , Brian S. Miller
IPC分类号： A61K9/127 , A61K31/70 , A61P11/00
摘要： Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.
摘要翻译：提供了一种治疗或改善囊性纤维化患者肺部感染的方法，包括向患者肺部施用有效量的脂质体/复合抗感染药，其中（i）给药量为50％或更少比较游离药物量，或（ii）给药是每天一次或更少，或（iii）两者。

9. 发明授权

US06793912B2 Treatment of cancers by inhalation of stable platinum-containing formulations 有权
标题翻译：通过吸入稳定的含铂制剂治疗癌症
公开(公告)号：US06793912B2
公开(公告)日：2004-09-21
申请号：US10224532
申请日：2002-08-20
申请人： Frank G. Pilkiewicz , Joel B. Portnoff , Lawrence T. Boni , Jin K. Lee
发明人： Frank G. Pilkiewicz , Joel B. Portnoff , Lawrence T. Boni , Jin K. Lee
IPC分类号： A61K912
CPC分类号： A61K9/0075 , A61K9/008 , A61K9/127 , A61K9/1277 , A61K31/282 , A61K31/555 , A61K33/24 , A61K38/40 , A61K45/06 , Y10S514/908 , A61K2300/00
摘要： Disclosed are methods of treating cancers by inhalation of stable platinum-containing formulations.
摘要翻译：公开了通过吸入稳定的含铂制剂治疗癌症的方法。

10. 发明授权

US6086851A Pharmaceutical compositions containing interdigitation-fusion liposomes and gels 失效
标题翻译：含有交叉指导 - 融合脂质体和凝胶的药物组合物
公开(公告)号：US6086851A
公开(公告)日：2000-07-11
申请号：US881651
申请日：1997-06-24
申请人： Lawrence T. Boni , Andrew S. Janoff , Sharma R. Minchey , Walter R. Perkins , Christine E. Swenson , Patrick L. Ahl , Thomas S. Davis
发明人： Lawrence T. Boni , Andrew S. Janoff , Sharma R. Minchey , Walter R. Perkins , Christine E. Swenson , Patrick L. Ahl , Thomas S. Davis
IPC分类号： A61K9/127 , A61K49/04 , A61L2/00 , B01J13/02 , B32B5/16
CPC分类号： A61K9/1277 , A61L2/0011 , Y10S436/829 , Y10T428/2984 , Y10T428/2989
摘要： This invention provides a composition containing a sized liposome comprising a lipid and an inducer; the sized liposome has a diameter of at most about 1 micron and the inducer is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdigitation-fusion liposomes and gels, and methods of making the same.
摘要翻译：本发明提供含有脂质体和脂质体的组合物，其包含脂质和诱导剂; 大小的脂质体具有至多约1微米的直径，并且诱导剂以有效诱导大小的脂质体的交叉指向融合的量存在。本文还提供了交叉指导 - 融合脂质体和凝胶，以及制备它们的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式